Prothena

Yahoo Finance • 2 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate... Full story

Yahoo Finance • 3 months ago

Prothena Corporation plc (PRTA): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesi... Full story

Yahoo Finance • 3 months ago

Bristol Myers Alzheimer's Drug Earns FDA Fast Track

This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to its experimental drug BMS-986446, now in phase 2 testing for patients in... Full story

Yahoo Finance • 3 months ago

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment... Full story

Yahoo Finance • 5 months ago

Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes

Prothena Corporation plc (NASDAQ:PRTA), a biotechnology company focused on developing novel therapies for neurodegenerative and rare peripheral amyloid diseases, has experienced significant shifts in its pipeline and market outlook. With a... Full story

Yahoo Finance • 5 months ago

Novo Nordisk boosts Prothena on plans for amyloidosis therapy

[New Nordisk] hapabapa/iStock Editorial via Getty Images * Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) shares spiked on Wednesday after Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) during its Q2 earnings ca... Full story

Yahoo Finance • 5 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program... Full story

Yahoo Finance • 5 months ago

Life360 Reaches Analyst Target Price

In recent trading, shares of Life360 Inc (Symbol: LIF) have crossed above the average analyst 12-month target price of $76.12, changing hands for $76.93/share. When a stock reaches the target an analyst has set, the analyst logically has... Full story

Yahoo Finance • 5 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash po... Full story

Yahoo Finance • 7 months ago

Prothena announces 63% workforce reduction following birtamimab halt

Prothena Corporation plc (NASDAQ:PRTA) announced a significant workforce reduction of approximately 63% to substantially reduce operating costs following its decision to discontinue development of birtamimab, according to an SEC filing on... Full story

Yahoo Finance • 7 months ago

Prothena to lay off 63% of workforce, revises full year guidance

* Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) has initiated an around 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining wholly owned programs, its obl... Full story

Yahoo Finance • 7 months ago

Prothena to cut workforce by 63% amid strategic review

DUBLIN - Prothena Corporation plc (NASDAQ:PRTA), currently trading at $5.75 and down over 70% in the past year, announced Wednesday it has initiated an approximate 63% reduction in its workforce to substantially reduce operating costs whil... Full story

Yahoo Finance • 7 months ago

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena Corporation plc (NASDAQ:PRTA), has announced plans to initiate Phase 3 development of prasinezumab for early-stage Parkin... Full story

Yahoo Finance • 7 months ago

Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies

[Parkinsons Disease Torn Paper Concept] IvelinRadkov * Shares of Prothena Corporation (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) added ~11% in the premarket on Monday after the biotech said its partner Roche (OTCQX:RHHBF [http... Full story

Yahoo Finance • 7 months ago

Roche to advance Parkinson's disease antibody to Phase III trials

DUBLIN - Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease, Prothena Corporation plc (NASDAQ:PRTA) announced Monday. The announcement comes as... Full story

Yahoo Finance • 8 months ago

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results

On May 27,  Jefferies downgraded Prothena Corporation plc (NASDAQ:PRTA) to Hold from Buy and slashed the price target to $6 from $32. The considerable price target reduction followed the company's announcement regarding the discontinuatio... Full story

Yahoo Finance • 11 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareho... Full story

Yahoo Finance • 2 years ago

We think Prothena Corporation plc's (NASDAQ:PRTA) CEO May Struggle To See Much Of A Pay Rise This Year

Key Insights Prothena to hold its Annual General Meeting on 14th of May Salary of US$630.5k is part of CEO Gene Kinney's total remuneration Total compensation is similar to the industry average Over the past three years, Prothena's EPS fe... Full story

Yahoo Finance • 2 years ago

Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results

Prothena Corp PLC (NASDAQ:PRTA) reported net income of $21.9 million for Q3 2023, compared to a net loss of $45.8 million for Q3 2022. The company received a $55 million payment from Bristol Myers Squibb for exclusive worldwide license to... Full story

Yahoo Finance • 3 years ago

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Data from oral presentation adds to growing body of evidence supporting the profile of PRX012, which is designed to target all aggregated forms of amyloid beta with high binding potency Demonstrated 20-fold higher affinity to amyloid beta... Full story